Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology


You May Also Like

Air Methods Acquires San Antonio AirLIFE

SAN ANTONIO, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Air Methods Corporation (NASDAQ:AIRM), the global ...

ContraFect Announces Third Quarter 2018 Financial Results

YONKERS, N.Y., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology ...